NASDAQ:CHRS Coherus Oncology (CHRS) Stock Price, News & Analysis $1.21 +0.03 (+2.54%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$1.20 -0.01 (-0.83%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Coherus Oncology Stock (NASDAQ:CHRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coherus Oncology alerts:Sign Up Key Stats Today's Range$1.16▼$1.2350-Day Range$1.13▼$1.4852-Week Range$1.09▼$2.62Volume1.58 million shsAverage Volume1.28 million shsMarket Capitalization$186.95 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview Coherus Oncology, Inc. (NASDAQ: CHRS) is a biopharmaceutical company focused on developing and commercializing medicines for cancer and other serious diseases. The company’s strategy has evolved from an initial emphasis on biosimilars toward oncology products, including therapies designed to support immune-based cancer treatment and address significant unmet medical needs. Coherus Oncology’s portfolio has included LOQTORZI (toripalimab-tpzi), an immunotherapy used with chemotherapy for certain patients with recurrent or metastatic nasopharyngeal carcinoma, as well as biosimilar products such as UDENYCA (pegfilgrastim-cbqv), CIMERLI (ranibizumab-eqrn) and YUSIMRY (adalimumab-aqvh). Its products have served markets in the United States, with commercialization and development activities also supported by international partnerships. Founded as Coherus BioSciences, the company built its business around the development of biosimilars before expanding into immuno-oncology through internal research, licensing arrangements and acquisitions, including the acquisition of Surface Oncology. The company subsequently adopted the Coherus Oncology name to reflect its focus on cancer therapies. Coherus Oncology is led by President and Chief Executive Officer Denny Lanfear.AI Generated. May Contain Errors. Read More Coherus Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCHRS MarketRank™: Coherus Oncology scored higher than 41% of companies evaluated by MarketBeat, and ranked 647th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCoherus Oncology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoherus Oncology has a consensus price target of $11.00, representing about 809.1% upside from its current price of $1.21.Amount of Analyst CoverageCoherus Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Coherus Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Coherus Oncology are expected to grow in the coming year, from ($0.88) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Oncology is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Oncology is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoherus Oncology has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coherus Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.94% of the float of Coherus Oncology has been sold short.Short Interest Ratio / Days to CoverCoherus Oncology has a short interest ratio ("days to cover") of 32.76, which indicates bearish sentiment.Change versus previous monthShort interest in Coherus Oncology has recently decreased by 4.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoherus Oncology does not currently pay a dividend.Dividend GrowthCoherus Oncology does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.76 News SentimentCoherus Oncology has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Coherus Oncology this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows2 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coherus Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders7.22% of the stock of Coherus Oncology is held by insiders.Percentage Held by Institutions72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Coherus Oncology's insider trading history. Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHRS Stock News HeadlinesEmergent Biosolutions (NYSE:EBS) vs. Coherus Oncology (NASDAQ:CHRS) Head-To-Head ComparisonSeptember 28 at 4:15 AM | americanbankingnews.comCoherus Oncology Starts Process to Sell Remaining Biosimilar AssetsSeptember 24, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Coherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR DetailsSeptember 23, 2026 | quiverquant.comQCoherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar AssetsSeptember 23, 2026 | globenewswire.comCoherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comCoherus to Participate in Upcoming Investor ConferencesAugust 31, 2026 | globenewswire.comCoherus Biosciences Launches $50 Million ATM Equity ProgramAugust 28, 2026 | tipranks.comSee More Headlines CHRS Stock Analysis - Frequently Asked Questions How have CHRS shares performed this year? Coherus Oncology's stock was trading at $1.42 at the start of the year. Since then, CHRS stock has decreased by 14.8% and is now trading at $1.21. How were Coherus Oncology's earnings last quarter? Coherus Oncology, Inc. (NASDAQ:CHRS) announced its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06. The biotechnology company had revenue of $14.31 million for the quarter, compared to analyst estimates of $14.41 million. Coherus Oncology had a negative trailing twelve-month return on equity of 222.75% and a negative net margin of 259.41%. Read the conference call transcript. Does Coherus Oncology have any subsidiaries? Coherus Oncology subsidiaries include these companies: InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc.. When did Coherus Oncology IPO? Coherus Oncology (CHRS) raised $85 million in an initial public offering on Thursday, November 6th 2014. The company issued 6,296,300 shares at a price of $12.00-$15.00 per share. How do I buy shares of Coherus Oncology? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coherus Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CHRS's financial health is in the Yellow zone, according to TradeSmith. CHRS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CHRS CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees144Year Founded2010Price Target and Rating Average Price Target for Coherus Oncology$11.00 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+809.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$168.02 million Net Margins-259.41% Pretax Margin-316.37% Return on Equity-222.75% Return on Assets-52.11% Debt Debt-to-Equity Ratio0.61 Current Ratio1.77 Quick Ratio1.70 Sales & Book Value Annual Sales$42.17 million Price / Sales4.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book2.42Miscellaneous Outstanding Shares154,500,000Free Float143,346,000Market Cap$186.95 million OptionableOptionable Beta0.94 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CHRS) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
